Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Adc Therapeutics Sa (NY: ADCT ) 3.070 +0.250 (+8.87%) Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Adc Therapeutics Sa < Previous 1 2 3 4 5 6 7 8 9 Next > ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q2 2024 August 06, 2024 ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update August 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Makes Grants to New Employees Under Inducement Plan August 01, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024 July 30, 2024 From ADC Therapeutics SA Via GlobeNewswire A Preview Of ADC Therapeutics's Earnings March 12, 2024 Via Benzinga 7 Growth Stocks to Buy for Under $5 for Massive Gains July 11, 2024 Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential. Via InvestorPlace Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session July 08, 2024 Via Benzinga ADC Therapeutics Makes Grants to New Employees Under Inducement Plan July 01, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes June 27, 2024 From ADC Therapeutics SA Via GlobeNewswire Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget June 13, 2024 Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. Via InvestorPlace ADC Therapeutics Makes Grants to New Employees Under Inducement Plan June 03, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 15, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference May 09, 2024 From ADC Therapeutics SA Via GlobeNewswire ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 06, 2024 ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session May 06, 2024 Via Benzinga ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants May 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates May 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma May 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Makes Grants to New Employees Under Inducement Plan May 01, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024 May 01, 2024 From ADC Therapeutics SA Via GlobeNewswire Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session April 30, 2024 Via Benzinga ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma April 04, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 April 03, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Makes Grants to New Employees Under Inducement Plan April 01, 2024 From ADC Therapeutics SA Via GlobeNewswire Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday March 13, 2024 U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates March 13, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit March 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 March 06, 2024 From ADC Therapeutics SA Via GlobeNewswire Earnings Scheduled For March 13, 2024 March 13, 2024 Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.